AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00886314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
Study NCT00886314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clown doctor
Description: Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
Study NCT04652102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVnCoV
Description: Intramuscular (IM) injection.
Study NCT04652102 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular (IM) injection.
Study NCT04652102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program
Description: Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.
Study NCT02516306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV06 Ophthalmic Solution
Study NCT02516306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Study NCT02416765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-hour intervention
Description: Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
Study NCT02416765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin (Lispro, Aspart or guilisine)
Description: Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
Study NCT02416765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (Eli Lilly)
Description: In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
Study NCT02416765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop strategy
Description: Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
Study NCT00338429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHP Sleep Program
Description: Cognitive-Behavioral Intervention
Study NCT03884556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-030
Description: Variable dose and schedule
Study NCT03884556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose and schedule per standard of care
Study NCT03884556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose and schedule per standard of care
Study NCT03884556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: Dose and schedule per standard of care
Study NCT02950311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal xylitol spray
Description: Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
Study NCT02950311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal saline spray
Description: Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
Study NCT01191138 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Infracolic gastrojejunal anastamosis
Description: Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
Study NCT01191138 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Supracolic gastrojejunal anastamosis
Description: Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
Study NCT00528840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
Study NCT03607240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung ultrasound-guided alveolar recruitment
Description: Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.
Study NCT03607240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional alveolar recruitment
Description: Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
Study NCT02967562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inflation Breaths
Study NCT02967562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Inflation
Study NCT01466439 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-frequency of repetitive transcranial magnetic stimulation (rTMS)
Description: frequency of stimulation of 20 Hz
Study NCT01466439 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: low frequency of repetitive transcranial magnetic stimulation (rTMS)
Description: frequency of stimulation of 1 Hz
Study NCT02254252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
Study NCT02027896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated medical clearance and surgery
Description: Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
Study NCT02709733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Motivation Training
Description: Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
Study NCT02875756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10 revolutions
Description: The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
Study NCT02875756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 20 revolutions
Description: The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
Study NCT04857905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microsurgical resection
Description: Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
Study NCT01142778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
Study NCT04857905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gamma Knife radiosurgery
Description: Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
Study NCT01142778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
Study NCT01142778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
Study NCT03198117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: a Chinese traditional medicine
Study NCT03198117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02205112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Study NCT02205112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Study NCT02866552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stromal Vascular fraction
Study NCT02866552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer lactate
Study NCT03759847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid intake app
Description: Use of fluid app to monitor intake of fluids
Study NCT03759847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
Study NCT01965275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib or Gefitinib
Description: Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
Study NCT02521610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
Study NCT02521610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7625
Description: Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
Study NCT04412824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous blood draw
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
Study NCT04412824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous blood draw
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
Study NCT03053284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.6Mg Solution for Injection
Description: Pasireotide 0.6Mg Solution for Injection will be given once per study visit
Study NCT03053284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline Solution injection will be given once per study visit
Study NCT01142778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
Study NCT01142778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
Study NCT03720106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GOAL therapy plan
Description: The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
Study NCT02458742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
Study NCT02458742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
Study NCT02016586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maternal Nutritional Supplement
Description: S348S0
Study NCT00662285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron supplement: Niferex 100 mg
Description: A: 100 mg pr day in 8 days
Study NCT03978286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 10 mg per day
Study NCT03978286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 75 mg per day
Study NCT06137989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fill-Up Class ӀӀ restoration
Description: Bulk-fill technique
Study NCT06137989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QuiXfil Class ӀӀ restoration
Description: Bulk-fill technique
Study NCT06137989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tetric N-Ceram Bulk Fill Class ӀӀ restoration
Description: Bulk-fill technique
Study NCT02237144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: 1500 taka ($18.75) per household distributed monthly
Study NCT02237144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food transfer
Description: 30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
Study NCT02237144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food and cash transfer
Description: 15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
Study NCT02237144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Communication Change (BCC)
Description: Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
Study NCT04075955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyprexa® (OLANZapine 5MG)
Description: Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)
Study NCT04075955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emend® (Aprepitant)
Description: Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)
Study NCT02079311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active self warming blanket
Description: BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
Study NCT02079311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced air warming device
Description: Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
Study NCT01970540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
Study NCT01970540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
Study NCT01142778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
Study NCT01142778 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
Study NCT01142778 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
Study NCT01142778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal Therapy
Description: Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
Study NCT01142778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal Therapy
Description: Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
Study NCT01016717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
Study NCT01016717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
Study NCT00737217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral assessment/questionnaire
Description: Complete behavioral assessment/questionnaire
Study NCT03476798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15mg/kg IV on day 1 of each cycle
Study NCT02054091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Description: The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
Study NCT02026739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low supplemental oxygen concentration
Description: low supplemental oxygen concentration would be used during the surgery
Study NCT03737409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory Oxygen Therapy
Description: Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
Study NCT03737409 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Ambulatory Oxygen Therapy
Description: Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
Study NCT00101920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-EGF
Description: 2.5 mg/kg by an infusion pump over one hour
Study NCT05366621 — intervention group
Intervention type: DRUG
Intervention: Anti-osteoporosis medications
Description: Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
Study NCT01907308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
Study NCT01907308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
Study NCT01825148 — intervention group
Intervention type: OTHER
Intervention: radiolabeled Exendin
Study NCT00089024 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).